Gene-editing technology empowers the development of drugs for rare diseases.
Release time:
2023-03-02
As gene-editing technologies continue to mature, their application in the development of drugs for rare diseases is becoming increasingly widespread.
As gene-editing technologies continue to mature, their application in the development of drugs for rare diseases is becoming increasingly profound. Research teams are leveraging CRISPR-Cas9 gene-editing technology to conduct precise repair studies targeting disease-causing genes associated with a variety of rare diseases, and have successfully demonstrated therapeutic efficacy in animal models. Based on these findings, several pharmaceutical companies have already initiated relevant clinical trials, aiming to translate gene-editing technologies into viable drug products. For the rare-disease patient community, this advancement is highly significant—it holds the promise of transforming the current situation, in which most rare diseases lack effective treatment options, and opens up an entirely new pathway for the development of rare-disease therapies.
Next
Address: 6th Floor, Building C6, Jiangsu Life Science and Technology Innovation Park, Qixia District, Nanjing City
Official account